查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552699

非何杰金氏淋巴瘤治療市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034 年

Non-Hodgkin's Lymphoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 135 Pages | 商品交期: 2-10個工作天內

價格

非何杰金氏淋巴瘤治療市場 - 報告範圍

TMR 關於全球非何杰金氏淋巴瘤治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2024 年至2034 年預測期內市場指標的寶貴見解。瘤治療市場的收入- 2018-2034年霍奇金淋巴瘤治療市場，考慮2024年為基準年，2034年為預測年。該報告也提供了2024年至2034年全球非何杰金氏淋巴瘤治療市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解非何杰金氏淋巴瘤治療市場。

市場概況
2023年市場價值 80 億美元
2034 年市場價值 186 億美元
複合年成長率 8%

該報告深入研究了全球非何杰金氏淋巴瘤治療市場的競爭格局。全球非何杰金氏淋巴瘤治療市場的主要參與者已經確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球非何杰金氏淋巴瘤治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依治療方法

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依治療方法，2020-2034
    • 化療
    • 標靶治療
    • 免疫療法
    • 其他（放射治療等）
  • 市場吸引力：依治療方法分類

第 7 章：全球市場分析與預測：依指標類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依指標類型，2020-2034
    • B 細胞淋巴瘤
    • T細胞淋巴瘤
  • 市場吸引力：依指示類型

第 8 章：全球市場分析與預測：按管理途徑

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2020-2034年
    • 口服
    • 注射用
  • 市場吸引力：依給藥途徑分類

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2020-2034
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力：按最終用戶分類

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Pfizer Inc.
    • GSK plc
    • Novartis AG
    • Bayer AG
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • AbbVie Inc.
    • AstraZeneca plc
    • Johnson & Johnson Pvt. Ltd.
Product Code: TMRGL2668

Non-Hodgkin's Lymphoma Therapeutics Market - Scope of Report

TMR's report on the global non-Hodgkin's lymphoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-Hodgkin's lymphoma therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-Hodgkin's lymphoma therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-Hodgkin's lymphoma therapeutics market.

Market Snapshot
Market Value in 2023US$ 8 Bn
Market Value in 2034US$ 18.6 Bn
CAGR8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-Hodgkin's lymphoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-Hodgkin's lymphoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-Hodgkin's lymphoma therapeutics market.

The report delves into the competitive landscape of the global non-Hodgkin's lymphoma therapeutics market. Key players operating in the global non-Hodgkin's lymphoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-Hodgkin's lymphoma therapeutics market profiled in this report.

Key Questions Answered in Global non-Hodgkin's lymphoma therapeutics Market Report:

  • What is the sales/revenue generated by non-Hodgkin's lymphoma therapeutics across all regions during the forecast period?
  • What are the opportunities in the global non-Hodgkin's lymphoma therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Non-Hodgkin's Lymphoma Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global non-Hodgkin's lymphoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-Hodgkin's lymphoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-Hodgkin's lymphoma therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-Hodgkin's Lymphoma Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Treatment Therapy

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Therapy, 2020-2034
    • 6.3.1. Chemotherapy
    • 6.3.2. Targeted Therapy
    • 6.3.3. Immunotherapy
    • 6.3.4. Others (Radiation Therapy, etc.)
  • 6.4. Market Attractiveness, by Treatment Therapy

7. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Indication Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication Type, 2020-2034
    • 7.3.1. B-Cell Lymphomas
    • 7.3.2. T-Cell Lymphomas
  • 7.4. Market Attractiveness, by Indication Type

8. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by End-user

10. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Therapy, 2020-2034
    • 11.2.1. Chemotherapy
    • 11.2.2. Targeted Therapy
    • 11.2.3. Immunotherapy
    • 11.2.4. Others (Radiation Therapy, etc.)
  • 11.3. Market Attractiveness, by Treatment Therapy
  • 11.4. Market Value Forecast, by Indication Type, 2020-2034
    • 11.4.1. B-Cell Lymphomas
    • 11.4.2. T-Cell Lymphomas
  • 11.5. Market Attractiveness, by Indication Type
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Oral
    • 11.6.2. Parenteral
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Treatment Therapy
    • 11.11.2. By Indication Type
    • 11.11.3. By Route of Administration
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Therapy, 2020-2034
    • 12.2.1. Chemotherapy
    • 12.2.2. Targeted Therapy
    • 12.2.3. Immunotherapy
    • 12.2.4. Others (Radiation Therapy, etc.)
  • 12.3. Market Attractiveness, by Treatment Therapy
  • 12.4. Market Value Forecast, by Indication Type, 2020-2034
    • 12.4.1. B-Cell Lymphomas
    • 12.4.2. T-Cell Lymphomas
  • 12.5. Market Attractiveness, by Indication Type
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Oral
    • 12.6.2. Parenteral
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Online Pharmacies
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Treatment Therapy
    • 12.11.2. By Indication Type
    • 12.11.3. By Route of Administration
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Therapy, 2020-2034
    • 13.2.1. Chemotherapy
    • 13.2.2. Targeted Therapy
    • 13.2.3. Immunotherapy
    • 13.2.4. Others (Radiation Therapy, etc.)
  • 13.3. Market Attractiveness, by Treatment Therapy
  • 13.4. Market Value Forecast, by Indication Type, 2020-2034
    • 13.4.1. B-Cell Lymphomas
    • 13.4.2. T-Cell Lymphomas
  • 13.5. Market Attractiveness, by Indication Type
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Oral
    • 13.6.2. Parenteral
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Online Pharmacies
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Treatment Therapy
    • 13.11.2. By Indication Type
    • 13.11.3. By Route of Administration
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment Therapy, 2020-2034
    • 14.2.1. Chemotherapy
    • 14.2.2. Targeted Therapy
    • 14.2.3. Immunotherapy
    • 14.2.4. Others (Radiation Therapy, etc.)
  • 14.3. Market Attractiveness, by Treatment Therapy
  • 14.4. Market Value Forecast, by Indication Type, 2020-2034
    • 14.4.1. B-Cell Lymphomas
    • 14.4.2. T-Cell Lymphomas
  • 14.5. Market Attractiveness, by Indication Type
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Oral
    • 14.6.2. Parenteral
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospital Pharmacies
    • 14.8.2. Retail Pharmacies
    • 14.8.3. Online Pharmacies
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Treatment Therapy
    • 14.11.2. By Indication Type
    • 14.11.3. By Route of Administration
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Treatment Therapy, 2020-2034
    • 15.2.1. Chemotherapy
    • 15.2.2. Targeted Therapy
    • 15.2.3. Immunotherapy
    • 15.2.4. Others (Radiation Therapy, etc.)
  • 15.3. Market Attractiveness, by Treatment Therapy
  • 15.4. Market Value Forecast, by Indication Type, 2020-2034
    • 15.4.1. B-Cell Lymphomas
    • 15.4.2. T-Cell Lymphomas
  • 15.5. Market Attractiveness, by Indication Type
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Oral
    • 15.6.2. Parenteral
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospital Pharmacies
    • 15.8.2. Retail Pharmacies
    • 15.8.3. Online Pharmacies
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Treatment Therapy
    • 15.11.2. By Indication Type
    • 15.11.3. By Route of Administration
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Mylan N.V.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Sanofi S.A.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Pfizer Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. GSK plc
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Novartis AG
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Bayer AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Eli Lilly and Company
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Merck & Co., Inc.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. AbbVie Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. AstraZeneca plc
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Johnson & Johnson Pvt. Ltd.
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
  • Table 02: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 03: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 04: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
  • Table 08: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 9: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
  • Table 13: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 14: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
  • Table 18: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 19: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
  • Table 23: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 24: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
  • Table 28: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
  • Table 29: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by Treatment Therapy, 2023
  • Figure 03: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Treatment Therapy, 2023
  • Figure 04: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by Indication Type, 2023
  • Figure 05: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Indication Type, 2023
  • Figure 06: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 07: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
  • Figure 09: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by End-user, 2023
  • Figure 10: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Region, 2023
  • Figure 11: Global Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
  • Figure 13: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
  • Figure 14: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 15: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 16: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
  • Figure 19: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by End-user, 2023
  • Figure 20: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
  • Figure 26: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 27: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
  • Figure 30: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 31: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
  • Figure 37: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 38: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
  • Figure 41: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 42: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
  • Figure 48: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 49: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
  • Figure 52: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 53: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
  • Figure 59: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 60: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
  • Figure 63: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 64: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
  • Figure 70: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
  • Figure 71: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
  • Figure 74: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
  • Figure 75: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034